Hypera (HYPE3) Q1 2025 earnings summary

Executive summary

• Net revenue for 1Q25 was R$1,080.9 million, down 40.8% year-over-year, mainly due to a working capital optimization process reducing client inventories and accounts receivable days.

• Sell-out grew 6.9% in 1Q25, with 6.0% growth in pharmaceutical retail and 20.6% in non-retail/institutional markets, outpacing net revenue decline.

• Operating cash flow reached a record R$570.0 million, up 18.9% from 1Q24, despite negative EBITDA and net earnings.

• Net income from continuing operations was negative at R$138.8 million, compared to a positive R$391.5 million in 1Q24.

• The company declared R$184.7 million in interest on equity and invested R$640.9 million in marketing, innovation, and capacity expansion.

Financial highlights

• Gross profit was R$510.3 million, a 54.2% decrease year-over-year, with gross margin dropping 13.9 percentage points to 47.2%.

• EBITDA from continuing operations was negative at R$148.5 million; net earnings from continuing operations were negative at R$138.8 million.

• Free cash flow increased 9.2% to R$348.2 million.

• Marketing expenses rose 40% year-over-year to R$367.2 million; selling expenses increased 21.9%.

• General and administrative expenses were R$86.2 million.

Outlook and guidance

• The working capital optimization process is expected to conclude in early 2Q25, aiming for sustainable growth and improved return on invested capital.

• Sell-out growth is expected to accelerate to 8% for 2025, supported by new product launches.

• Gross margin is expected to normalize above 60% and EBITDA margin to return to 35% in Q2 2025.

• Marketing and selling expenses are expected to remain at current levels, with more balanced distribution throughout the year.

• CapEx for 2025 is expected to be below last year’s level.